Pancreatic Cancer Research

ResearcherUniversity of Occupational and Environmental Health JapanNo recent work listed

Koji Yamaguchi

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-8758-6598; OpenAlex author ID A5100606846. Sources: OpenAlex.

Their work

Papers
12 (first author 0, last author 1)
Trials
0
Grants
0
Labs led
0
Collaborators
40
Papers, trials and grants by year

2011: 3 papers · 2012: 2 papers · 2013: none · 2014: 3 papers · 2015: 2 papers · 2016: 1 paper · 2017: 1 paper

Papers 12

  1. Clinical Practice Guidelines for Pancreatic Cancer 2016 From the Japan Pancreas Society: A Synopsis. Co-author DOI 10.1097/mpa.0000000000000816↗
  2. International Association of Pancreatology (IAP)/European Pancreatic Club (EPC) consensus review of guidelines for the treatment of pancreatic cancer. Co-author DOI 10.1016/j.pan.2015.10.013↗
  3. [Algorithm for treatment of pancreatic cancer]. Co-author PMID 25856999↗
  4. [Clinical guidelines of pancreatic cancer 2013: a synopsis]. Co-author PMID 25857055↗
  5. Prognostic significance of WNT signaling in pancreatic ductal adenocarcinoma. Co-author DOI 10.1007/s00428-014-1642-2↗
  6. EBM-based Clinical Guidelines for Pancreatic Cancer (2013) issued by the Japan Pancreas Society: a synopsis. Co-author DOI 10.1093/jjco/hyu127↗
  7. Mitochondrial transcription factor a worsens the clinical course of patients with pancreatic cancer through inhibition of apoptosis of cancer cells. Last author DOI 10.1097/mpa.0000000000000049↗
  8. Association of microRNA-21 expression with its targets, PDCD4 and TIMP3, in pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/modpathol.2011.142↗
  9. [Pancreatic tumor: progress in diagnosis and treatment. Topics: I. Pancreatic carcinoma; 6. Evidence based clinical practice guidelines for pancreatic cancer 2… Co-author DOI 10.2169/naika.101.43↗
  10. EBM-based Clinical Guidelines for Pancreatic Cancer 2009 from the Japan Pancreas Society: a synopsis. Co-author DOI 10.1093/jjco/hyr077↗
  11. Pancreatic ductal adenocarcinoma derived from IPMN and pancreatic ductal adenocarcinoma concomitant with IPMN. Co-author DOI 10.1097/mpa.0b013e318215010c↗
  12. How to define patients at high risk for pancreatic cancer. Co-author DOI 10.1159/000323477↗

Closest collaborators

The 25 strongest of 40 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Junji Furuse · 3 shared papers, 2014–2017 · strength 0.14
  2. Keiji Hanada · 3 shared papers, 2011–2017 · strength 0.12
  3. Noritaka Minagawa · 2 shared papers, 2012–2014 · strength 0.12
  4. Tooru Shimosegawa · 2 shared papers, 2014–2017 · strength 0.10
  5. Takuji Okusaka · 2 shared papers, 2014–2017 · strength 0.10
  6. Masao Tanaka · 2 shared papers, 2011 · strength 0.08
  7. Masanori Hisaoka · 2 shared papers, 2012–2014 · strength 0.08
  8. Kazuichi Okazaki · 1 shared paper, 2017 · strength 0.07
  9. Masumi Yamauchi · 1 shared paper, 2014 · strength 0.05
  10. Takashi Hatori · 2 shared papers, 2011–2014 · strength 0.05
  11. Mitsuhiro Nakamoto · 1 shared paper, 2014 · strength 0.05
  12. Colin Johnson · 1 shared paper, 2016 · strength 0.04
  13. John Albert Windsor · 1 shared paper, 2016 · strength 0.04
  14. Thomas Baptist Brunner · 1 shared paper, 2016 · strength 0.04
  15. Francesco Sclafani · 1 shared paper, 2016 · strength 0.04
  16. Christopher Lee Wolfgang · 1 shared paper, 2016 · strength 0.04
  17. John P. Neoptolemos · 1 shared paper, 2016 · strength 0.04
  18. Claudio Bassi · 1 shared paper, 2016 · strength 0.04
  19. Massimo Falconi · 1 shared paper, 2016 · strength 0.04
  20. Marc F. Giovannini · 1 shared paper, 2016 · strength 0.04
  21. David Cunningham · 1 shared paper, 2016 · strength 0.04
  22. Adam Enver Frampton · 1 shared paper, 2016 · strength 0.04
  23. Andrew Victor Biankin · 1 shared paper, 2016 · strength 0.04
  24. Aldo Scarpa · 1 shared paper, 2016 · strength 0.04
  25. Francisco X. Real · 1 shared paper, 2016 · strength 0.04

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.